Most Popular
Research Trends
Searching for Better Lung Cancer Models - KS Mice
Mar 18, 2024
In this issue, we introduce the KS mouse model of lung cancer, based on the most common cancer-associated K-Ras mutant, K-Ras(G12D). Lung cancer is the most common cancer worldwide, with over 2.2 million new cases reported globally in 2020. According to data released by the Chinese National Cancer Center, lung cancer had already become the leading cause of morbidity and mortality among all malignant tumors in China by 2015. Read More >
Research Trends
Beta Thalassemia Research: Hbb-bs&Hbb-bt DKO Mouse Models
Mar 14, 2024
In this edition, we provide an overview of Beta Thalassemia (β-thalassemia), a genetic blood disorder caused by reduced or absent synthesis of the beta globin (β-globin) chain of hemoglobin, and introduce Hbb-bs&Hbb-bt DKO mice as a promising Beta-thalassemia research model for preclinical therapeutics. Beta-thalassemia is one of the global social and public health issues monitored by the World Health Organization (WHO). Read More >
Research Trends
Small Nucleic Acid Drug Evaluation Model for Spinal Muscular Atrophy Research - B6-hSMN2(SMA) Mice
Feb 29, 2024
Today, we'll be introducing a model of Spinal Muscular Atrophy (SMA) - B6-hSMN2(SMA) mice. But before delving into this mouse model, let's first introduce the basic pathology of SMA. Read More >
Research Trends
Preclinical R&D Interest Soars as the First AAV Gene Therapy for DMD Hits $200 Million in Sales
Feb 22, 2024
Jointly developed by Sarepta Therapeutics and Roche, ELEVIDYS is an adeno-associated virus vector-based gene therapy indicated for the treatment of ambulatory pediatric patients aged 4 - 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. The United States Food and Drug Administration authorized accelerated approval for this indication based on expression of ELEVIDYS micro-dystrophin in skeletal muscle observed in patients treated with ELEVIDYS in June 2023. Read More >
Research Trends
Obesity Research Mice Introduction (Part 2): Non-LEP/LEPR Genetic Models
Feb 18, 2024
In our previous article, we provided an “Introduction to Murine Models of Obesity (Part 1): LEP/LEPR Classic Pathway Model”. In this edition, we will delve into non-LEP/LEPR genetic mouse models for obesity research. Read More >
Research Trends
Introduction to Murine Models of Obesity (Part 1): LEP/LEPR Classic Pathway Model
Jan 31, 2024
To effectively conduct research on obesity and its prevention and treatment, it is crucial to comprehend the mechanisms underlying obesity. Leveraging mouse models of obesity-related diseases is essential for gaining meaningful insights into the prevention and treatment of obesity and its complications. Read More >
Research Trends
Challenges of Performing Orthotopic Colorectal Cancer Modeling: Evaluating the Effectiveness of Modeling Site Exploration
Jan 26, 2024
Colorectal cancer is a common malignant tumor that occurs in the colon, predominantly in the junction between the rectum and sigmoid colon. It ranks as the third most common gastrointestinal tumor with the highest incidence in the age group of 40 to 50 years, with a male-to-female ratio of 2-3:1. Read More >
Newsletter
Breaking News
Cyagen Congratulates Our Partner INNOVEC on Receiving FDA Pediatric Rare Disease Designation (RPDD) for IVB102 Injection
Jan 23, 2024
The United States Food and Drug Administration (FDA) granted Beijing InnoVec Biotherapeutics’ InnoVex IVB102 injection the Rare Pediatric Disease Designation (RPDD) on January 10, 2024. Innovec is now one step closer to being eligible for the Rare Pediatric Disease Priority Review Voucher (PRV) for the treatment of rare pediatric diseases with the InnoVex IVB102 injection in the United States. Read More >
Research Trends
Circumventing Difficulties in Dynamic Monitoring of Orthotopic Tumor Transplantation Models with In Vivo Bioluminescent Imaging
Jan 12, 2024
Compared to the traditional method of euthanizing animals in batches to obtain experimental data, real-time bioluminescence imaging (BLI) technology allows for qualitative and quantitative observations at the cellular and molecular levels of a living organism. Read More >
Ten Deadly Sins of Rare Diseases
Unraveling Rare Diseases: Researching Hotspot Pathogenic Mutations in Humanized Models
Dec 29, 2023
Welcome to the 'Ten Deadly Sins of Rare Diseases' column, where we decode the pathogenic mechanisms of rare diseases, industry research progress (e.g. gene therapy), and innovative pre-clinical strategies to drive translational research results (such as model construction and drug screening, etc.). Read More >